An Unusual Presentation From a Sporadic **Partially Acid-Fast Aerobic Actinomycete Resistant to Common Antibiotics**

Journal of Investigative Medicine High Impact Case Reports Volume 8: I-3 © 2020 American Federation for Medical Research DOI: 10.1177/2324709619899598 journals.sagepub.com/home/hic



Sreedhar Adapa, MD¹, Srikanth Naramala, MD², Vijay Gayam, MD^3 , Rajan Kapoor, MD^4 , Mina Raju, DO^5 , Pallav Patel, MD⁵, and Venu Madhav Konala, MD⁶[™]

Abstract

Nocardia causes rare opportunistic infections, that can be challenging to diagnose because of atypical features on conventional microbiological identification techniques. Immunosuppressed patients are more susceptible to infections from Nocardia and are associated with multi-organ involvement. We report a case of a 63-year-old male who developed peritonitis from Nocardia farcinica that rarely causes infections in humans. The nonspecific symptoms, negative blood cultures, and slow growth can make diagnosis difficult. Despite aggressive therapy, the virulence and inherent resistance to the antibiotics can result in high mortality from Nocardia farcinica infections.

Keywords

Nocardia, Nocardia farcinica, immunocompromised, peritonitis

Introduction

Nocardia species are opportunistic organisms, which can rarely cause infections in humans.¹ Peritonitis is encountered in the patients undergoing peritoneal dialysis and often can be severe. Improved microbiological techniques are being frequently used to identify the uncommon organisms causing peritonitis.² We present a case of peritonitis from *N farcinica*, which was reported only once in literature before.³

Case Report

A 63-year-old male on peritoneal dialysis presented to the home dialysis clinic with a chief complaint of cloudy effluent. The patient was started on empiric intraperitoneal vancomycin and gentamicin for suspected peritonitis as the patient was allergic to penicillin. The patient developed severe itching, rash, and dry heaves after 10 minutes of intraperitoneal antibiotics dwell and was drained. The patient was sent to the emergency room for further management. The patient also had bilateral lower extremity cellulitis for 2 weeks, which was not getting better with oral cefalexin as an outpatient. He also admitted that he was not able to ambulate for a week and was having excruciating pain in the lower extremities on ambulating only short distances. The patient was admitted to the hospital for management of peritonitis and cellulitis. He was started on intravenous daptomycin and aztreonam.

The past medical history was significant for atrial fibrillation, type 2 diabetes, coronary artery disease, coronary artery bypass grafting, end-stage renal disease on peritoneal dialysis, mechanical mitral, and aortic valve repair on anticoagulation, implantable cardioverter-defibrillator. Outpatient medications include alprazolam 2 mg twice a day, bupropion 150 mg twice a day, calcitriol 0.25 µg daily, carvedilol 25 mg twice a day, furosemide 80 mg daily, losartan 100 mg daily, simvastatin 80 mg daily, and warfarin 3 mg daily. The patient was an ex-smoker and denied any intake of alcohol or drugs. Physical examination showed implantable cardioverterdefibrillator placement, has a mechanical click at the left lower sternal border, soft systolic ejection murmur, peritoneal dialysis catheter in place with no exit site infection, and bilateral lower extremity ulcerations, which had an

¹The Nephrology Group, Fresno, CA, USA ²Adventist Medical Center, Hanford, CA, USA ³Interfaith Medical Center, Brooklyn, NY, USA ⁴Augusta University Medical Center, Augusta, GA, USA ⁵Kaweah Delta Medical Center, Visalia, CA, USA ⁶Ashland Bellefonte Cancer Center, Ashland, KY, USA

Received November 21, 2019. Revised December 6, 2019. Accepted December 11, 2019.

Corresponding Author:

Sreedhar Adapa, The Nephrology Group, 568 E. Herndon Ave, Suite 201, Fresno, CA 93720, USA. Email: sadapa@kdhcd.org



Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Table 1. Susceptibilities of Nocardia farcinica.

Antibiotic	Minimal Inhibitory Concentration, µg/mL	Sensitive (S), Resistant (R), or Intermediate (I)
Amikacin	≤0.5	S
Amoxicillin + clavulanate	4	S
Cefepime	>32	R
Cefotaxime	32	I
Ceftriaxone	32	I
Ciprofloxacin	>2	R
Clarithromycin	>16	R
Doxycycline	8	R
Imipenem	2	S
Linezolid	2	S
Minocycline	4	I
Moxifloxacin	2	I
Tobramycin	16	R
Trimethoprim- sulfamethoxazole	≤1/20	S

eschar with surrounding erythema and were exquisitely tender on palpation.

The peritoneal fluid analysis sent from the dialysis clinic revealed 206 nucleated cells, 5% segmented neutrophils, 90% lymphocytes, and 5% eosinophils. The antibiotics were continued for 2 days in the hospital and were stopped as there was no growth in the peritoneal dialysis fluid, and repeated cell counts remained insignificant. The infectious disease specialist actively followed the patient since the day of admission to the hospital. During the hospitalization, the patient was evaluated by the vascular surgeon for nonhealing lower extremity ulcers. The patient was started on sodium thiosulfate for suspected calciphylaxis. The patient underwent lower extremity angiogram with right anterior tibial artery angioplasty for excruciating right lower extremity pain, which was cold and appeared necrotic. The patient developed retroperitoneal hematoma post angioplasty, secondary to supratherapeutic international normalized ratio, and the patient was managed conservatively by stopping warfarin for 3 days and administering fresh frozen plasma. The pain became unbearable for the patient despite angioplasty, and the patient underwent right above knee amputation. The patient subsequently developed left lower extremity pain and blisters during the hospital stay, and the patient underwent angiogram with angioplasty and recanalization of the totally occluded left anterior tibial artery. The vascular interventions and retroperitoneal hematoma prolonged the hospital stay. The patient continued to receive renal replacement therapy through peritoneal dialysis.

One month into the hospital admission, the peritoneal fluid was analyzed for suspicion of peritonitis, as the effluent was cloudy. Peritoneal fluid cell count revealed 3520 nucleated cells, 41 red blood cells, 91% neutrophils, 1% lymphocyte,

8% eosinophils, and gram stain revealed more than 100 white blood cells/low-power field; no organisms were seen. The patient was started on empiric intraperitoneal amikacin and ceftriaxone. The effluent culture from aerobic bottle grew Nfarcinica, identified by MALDI-TOF (matrix-assisted desorption ionization time-of-flight) technique. Oral linezolid was added to the antibiotic regimen after the organism was identified. The susceptibilities are mentioned in Table 1. The general surgery team removed the peritoneal dialysis catheter. Computed tomography of the head, chest, abdomen, and pelvis was done for suspected disseminated nocardiosis, which revealed discrete noncalcified mass measuring 3.3 cm in the left apex. Mixed density masses identified in the right lower abdominal quadrants of 4.1 cm and 5.9 cm that could represent infectious or prior resolving retroperitoneal hematoma. The patient's family opted against any aggressive interventions, including the biopsy of the lung mass, and it was decided to treat with oral linezolid for 6 months. The patient passed away, unfortunately, despite treatment as the clinical condition deteriorated.

Discussion

Nocardia species are aerobic, weakly gram-positive, partially acid-fast, methenamine silver-positive aerobic actinomycete. The bacterium is characterized by filamentous branches measuring less than 1 μ m thick and are not identified by conventional staining.⁴

Nocardia contains more than 100 species and is widely distributed in the environment in water, soil, decaying vegetation, and organic matter.⁵ The most important species implicated in human diseases is *Nocardia asteroids*. Other clinically relevant species are *N brazeliensis*, *N farcinica*, *N nova*, *N pseudobrasiliensis*, and *N transvalensis*.⁴ Accurate identification of species is essential because of the difference in the spectrum of diseases that they can cause and variations in their antimicrobial susceptibilities.

Nocardia farcinica is an uncommon cause for nocardiosis, particularly in immunocompetent individuals. It frequently involves adult males, but cases have been reported in children and females. It can cause nonspecific symptoms and signs, which often makes the early diagnosis difficult. Most common routes of infection are by inhalation or by percutaneous inoculation.⁵ Patients who have underlying malignancy, human immunodeficiency virus, dialysis dependence, receiving chemotherapy, and autoimmune disease are susceptible to *N farcinica* infections. It can cause multi-organ involvement and can cause life-threatening infections.⁵

Nocardia farcinica was infrequently isolated but could be related to the underdiagnosis of the organism. Recent changes in diagnostic technologies made the organism to be isolated more. It is highly virulent and is known to be naturally resistant to multiple antibiotics.⁴ Prompt diagnosis and timely treatment can be lifesaving.

Nocardia farcinica is a very slow-growing organism and can take up to more than 5 days to be identified. The blood cultures in patients with *N farcinica* infection are frequently negative as in our patient. Early diagnosis is made by the tissue culture, phenotypic and molecular methods, and 16S rRNA (recombinant ribonucleic acid) gene sequencing technique.¹

The susceptibilities for antibiotics are specific for *N farcinica*, but is often resistant to commonly used antibiotics as in our patient. Most commonly used antibiotic is trimethoprimsulfamethoxazole, but usually a combination of antibiotics like amikacin, moxifloxacin, imipenem-cilastatin, trimethoprim-sulfamethoxazole, and linezolid is needed.^{1,4,5} In patients with disseminated infections, prolonged treatment is required ranging from 6 months to 1 year.¹ Despite aggressive therapy, the mortality has been reported as high as 39%.⁴

Conclusion

This case highlights that rare organisms like *N farcinica* can cause peritonitis. Recently, advances in microbiological identification techniques has aided in isolating the organism. This case report also discusses the virulence and mortality of the organism.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethics Approval

Our institution does not require ethical approval for reporting individual cases or case series.

Informed Consent

Verbal informed consent was obtained from the patient(s) for their anonymized information to be published in this article.

ORCID iDs

Sreedhar Adapa D https://orcid.org/0000-0001-5608-5654 Rajan Kapoor D https://orcid.org/0000-0002-8633-7717 Venu Madhav Konala D https://orcid.org/0000-0003-1953-8815

References

- Boamah H, Puranam P, Sandre RM. Disseminated *Nocardia farcinica* in an immunocompetent patient. *IDCases*. 2016;6: 9-12.
- Adapa S, Gumaste P, Konala VM, Agarwal N, Garcha AS, Dhingra H. Peritonitis due to *Moraxella osloensis*: an emerging pathogen. *Case Rep Nephrol*. 2018;2018:4968371.
- Liassine N, Rahal K. Peritonitis caused by *Nocardia farcinica* in a patient undergoing continuous ambulatory peritoneal dialysis (note) [in French]. *Arch Inst Pasteur Alger*. 1992;58: 95-102.
- Budzik JM, Hosseini M, Mackinnon AC Jr, Taxy JB. Disseminated *Nocardia farcinica*: literature review and fatal outcome in an immunocompetent patient. *Surg Infect (Larchmt)*. 2012;13:163-170.
- Zhu N, Zhu Y, Wang Y, Dong S. Pulmonary and cutaneous infection caused by *Nocardia farcinica* in a patient with nephrotic syndrome: a case report. *Medicine (Baltimore)*. 2017; 96:e7211.